At the Cabinet’s weekly meeting Thursday, Premier Su Tseng-chang applauded strong results from the Ministry of Science and Technology’s (MOST) Biomedical Industry Innovation Program in 2018, including overall revenue growth of 5.5 percent to NT$514.1 billion (US$17 billion), and higher numbers of drug and device approvals received domestically and abroad. Taiwan also became a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use last ye